Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that
U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.
Filed: 2026-09-02 AccNo: 0001193125-26-380215 Size: 388 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.62) by 5.63 percent. This is a 31.54 percent decrease over losses of $(3.71) per share